Highlight
This study evaluates the impact of baseline cytogenetic abnormalities on clinical outcomes in multiple myeloma patients who achieve stringent measurable residual disease (MRD) negativity after autologous stem cell transplantation (ASCT). Key findings include:
1. Despite uniform MRD negativity, patients harboring certain high-risk cytogenetic abnormalities (HRCAs) experience notably poorer progression-free survival (PFS).
2. Isolated del(17p) and 1q21+ abnormalities confer inferior prognosis.
3. The burden of having multiple HRCAs correlates with further diminished PFS.
4. These observations emphasize persistent high-risk biological behavior after ASCT, underscoring the need for ongoing risk stratification beyond MRD metrics.
